The KOASTAL-1 study enrolled 383 adult patients with MDD. Navacaprant was shown to be safe and generally well-tolerated with ...

Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...

Neuroscience company Neumora Therapeutics (NMRA) announced today that its experimental treatment for depression, Navacaprant, ...

The biotech reported data from KOASTAL-1, the first of three phase 3 trials of navacaprant in major depressive disorder.

Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

BofA analyst Geoff Meacham lowered the firm’s price target on Neumora Therapeutics (NMRA) to $7 from $22 and keeps a Buy rating on the shares.

Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and ...

Neumora Therapeutics ( NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a ...

Shares of Neumora Therapeutics, Inc. (NMRA) are down more than 80% at $1.81 in premarket trading Thursday, following the release of ...

Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that ...